Insider Selling: Chemed Co. (NYSE:CHE) Director Sells 284 Shares of Stock

Chemed Co. (NYSE:CHE) Director Patrick P. Grace sold 284 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total value of $153,638.32. Following the sale, the director now owns 3,270 shares of the company’s stock, valued at approximately $1,769,004.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Chemed Stock Performance

NYSE CHE opened at $538.76 on Friday. Chemed Co. has a twelve month low of $492.84 and a twelve month high of $654.62. The stock has a market capitalization of $8.16 billion, a PE ratio of 29.00, a P/E/G ratio of 2.22 and a beta of 0.46. The stock has a 50-day simple moving average of $572.23 and a 200 day simple moving average of $591.40.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing the consensus estimate of $5.09 by ($0.41). Chemed had a return on equity of 30.52% and a net margin of 12.36%. The business had revenue of $589.23 million for the quarter, compared to analyst estimates of $587.18 million. As a group, equities research analysts forecast that Chemed Co. will post 21.54 EPS for the current fiscal year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Thursday, May 30th will be issued a $0.40 dividend. The ex-dividend date is Thursday, May 30th. This represents a $1.60 annualized dividend and a yield of 0.30%. Chemed’s dividend payout ratio (DPR) is 8.61%.

Analyst Ratings Changes

Several analysts have recently issued reports on CHE shares. StockNews.com upgraded Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Royal Bank of Canada decreased their price target on Chemed from $712.00 to $697.00 and set an “outperform” rating for the company in a research note on Tuesday, May 21st. Finally, Oppenheimer upped their price target on Chemed from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th.

Hedge Funds Weigh In On Chemed

Several large investors have recently added to or reduced their stakes in the company. Wealth Alliance raised its holdings in Chemed by 3.0% in the 4th quarter. Wealth Alliance now owns 578 shares of the company’s stock valued at $338,000 after acquiring an additional 17 shares in the last quarter. EntryPoint Capital LLC raised its holdings in Chemed by 14.0% in the 1st quarter. EntryPoint Capital LLC now owns 147 shares of the company’s stock valued at $94,000 after acquiring an additional 18 shares in the last quarter. Legacy Wealth Asset Management LLC raised its holdings in Chemed by 0.9% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 2,275 shares of the company’s stock valued at $1,330,000 after acquiring an additional 21 shares in the last quarter. Signaturefd LLC raised its holdings in Chemed by 5.8% in the 4th quarter. Signaturefd LLC now owns 385 shares of the company’s stock valued at $225,000 after acquiring an additional 21 shares in the last quarter. Finally, Covestor Ltd raised its holdings in Chemed by 10.6% in the 1st quarter. Covestor Ltd now owns 219 shares of the company’s stock valued at $141,000 after acquiring an additional 21 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.